The antibody response after the third dose (booster) is weaker in cancer patients, especially breast cancer patients aged ≥65 years old, those with intermediate and advanced stages, those with the HR–/Her2+, and those receiving anti-cancer therapy. Here, ERBB2 is linked to breast cancer.